CL2014002929A1 - Composicion que comprende ácido poliinosínico - policitidílico (poli (i:c) ) y un polimero portador; y sus usos para el tratamiento de infecciones de las vías respiratorias altas. - Google Patents
Composicion que comprende ácido poliinosínico - policitidílico (poli (i:c) ) y un polimero portador; y sus usos para el tratamiento de infecciones de las vías respiratorias altas.Info
- Publication number
- CL2014002929A1 CL2014002929A1 CL2014002929A CL2014002929A CL2014002929A1 CL 2014002929 A1 CL2014002929 A1 CL 2014002929A1 CL 2014002929 A CL2014002929 A CL 2014002929A CL 2014002929 A CL2014002929 A CL 2014002929A CL 2014002929 A1 CL2014002929 A1 CL 2014002929A1
- Authority
- CL
- Chile
- Prior art keywords
- polyinosinic
- poly
- treatment
- composition
- upper respiratory
- Prior art date
Links
- 206010057190 Respiratory tract infections Diseases 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12166595 | 2012-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014002929A1 true CL2014002929A1 (es) | 2015-01-16 |
Family
ID=48430695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014002929A CL2014002929A1 (es) | 2012-05-03 | 2014-10-29 | Composicion que comprende ácido poliinosínico - policitidílico (poli (i:c) ) y un polimero portador; y sus usos para el tratamiento de infecciones de las vías respiratorias altas. |
Country Status (18)
Country | Link |
---|---|
US (3) | US9682096B2 (es) |
EP (1) | EP2846767B1 (es) |
JP (1) | JP6349304B2 (es) |
KR (1) | KR102240042B1 (es) |
CN (1) | CN104394846B (es) |
AU (1) | AU2013255885C1 (es) |
BR (1) | BR112014026957A8 (es) |
CA (1) | CA2866230C (es) |
CL (1) | CL2014002929A1 (es) |
CO (1) | CO7101247A2 (es) |
ES (1) | ES2911116T3 (es) |
HK (1) | HK1203390A1 (es) |
IN (1) | IN2014MN02359A (es) |
MX (1) | MX2014013256A (es) |
NZ (1) | NZ630040A (es) |
RU (1) | RU2650636C2 (es) |
SG (2) | SG10201607288VA (es) |
WO (1) | WO2013164380A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013255885C1 (en) | 2012-05-03 | 2018-04-26 | Janssen Sciences Ireland Uc | Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections |
KR20160072140A (ko) * | 2013-11-06 | 2016-06-22 | 얀센 사이언시즈 아일랜드 유씨 | 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형 |
GB201415381D0 (en) * | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
US20180353533A1 (en) * | 2015-05-11 | 2018-12-13 | Janssen Sciences Ireland Uc | Polyinosinic-polycytidylic acid (poly (i:c)) pea starch formulation for the prevention and/or treatment of upper respiratory tract infections |
CN112294757B (zh) | 2015-11-17 | 2024-02-13 | 亮点医疗有限责任公司 | 包含含有双链聚核糖核苷酸与聚亚烷基亚胺的复合物的粒子的医药组合物 |
CA3006563A1 (en) * | 2015-11-30 | 2017-06-08 | Catherine Crisp TURKEL | Compositions and methods for otologic prophylaxis and treatment |
US20200060972A1 (en) | 2016-11-16 | 2020-02-27 | Janssen Sciences Ireland Unlimited Company | Formulations of polyinosinic acid and polycytidylic acid for the prevention of upper respiratory tract infections |
CN115998757A (zh) | 2017-05-17 | 2023-04-25 | 亮点医疗有限责任公司 | 包含具有双链多核糖核苷酸和聚乙烯亚胺的复合物的粒子的新型药物组合物 |
JP7296644B2 (ja) * | 2018-06-29 | 2023-06-23 | 信福(北京)医▲薬▼科技有限公司 | 免疫応答を強化するための複合物の調製方法 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
KR100259989B1 (ko) | 1991-10-01 | 2000-08-01 | 모리다 가쓰라 | 서방성 마이크로캡슐 제제 및 그의 제조법 |
GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
TW577759B (en) | 1997-04-18 | 2004-03-01 | Ipsen Pharma Biotech | Sustained release compositions in the form of microcapsules or implants and the process for their preparation |
CA2203843C (en) * | 1997-04-28 | 2013-07-23 | Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence | Liposome-encapsulated poly iclc |
MA25590A1 (fr) * | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | Agent actif de delivraison de poudre seche |
AU9445801A (en) * | 2000-10-06 | 2002-04-15 | Bioglan Ab | Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight |
AU2003287332A1 (en) * | 2002-11-01 | 2004-06-07 | The Regents Of The University Of California | Methods of treating pulmonary fibrotic disorders |
US7638138B2 (en) | 2003-02-21 | 2009-12-29 | Translational Research, Ltd. | Compositions for nasal administration of pharmaceuticals |
WO2005014038A1 (ja) | 2003-08-11 | 2005-02-17 | The Research Foundation For Microbial Diseases Of Osaka University | 粘膜免疫誘導アジュバントを含む新規ワクチン |
JP4772693B2 (ja) * | 2003-12-11 | 2011-09-14 | ヴァックスデザイン・コーポレーション | 免疫治療組成物、その製造方法及び使用方法 |
CN101229378A (zh) | 2005-05-05 | 2008-07-30 | 国家淀粉及化学投资控股公司 | 用于送递活性剂的组合物 |
DK1898948T3 (da) | 2005-06-08 | 2012-04-23 | Yisheng Biopharma Singapore Pte Ltd | Polyriboinosinsyre-polyribocytidylsyre-baseret adjuvans |
US20070166239A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
JP5270542B2 (ja) | 2006-07-22 | 2013-08-21 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
CL2007002218A1 (es) | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
AR067997A1 (es) * | 2007-08-24 | 2009-10-28 | Novartis Ag | Compuestos organicos |
JP2009209086A (ja) * | 2008-03-04 | 2009-09-17 | Masami Moriyama | 粘膜投与型ワクチン |
UA90013C2 (ru) * | 2008-03-19 | 2010-03-25 | Давид Анатолійович Нога | Фармацевтическая композиция, содержащая инсулин, и способ его получения |
EP2116602A1 (en) | 2008-05-07 | 2009-11-11 | Institut Gustave Roussy | Combination products for treating cancer |
EP2379059A4 (en) * | 2008-12-10 | 2012-10-31 | Anhui Zhongren Technology Co Ltd | COMPOSITION WITH CONTROLLED RELEASE |
CN101491503A (zh) | 2008-12-17 | 2009-07-29 | 天津瑞普生物技术股份有限公司 | 一种用于宠物的聚肌胞滴丸及其制备方法 |
WO2010073247A2 (en) | 2008-12-22 | 2010-07-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Egfr-homing double-stranded rna vector for systemic cancer treatment |
CN101757018A (zh) | 2008-12-24 | 2010-06-30 | 天津瑞普生物技术股份有限公司 | 一种用于畜禽的聚肌胞干粉及其制备方法 |
AU2010232180B2 (en) | 2009-03-31 | 2016-09-22 | Japan As Represented By The Director-General Of National Institute Of Infectious Diseases | Method for prophylaxis of influenza using vaccine for intranasal administration |
JP2013535457A (ja) | 2010-07-28 | 2013-09-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系及び炎症性疾患の治療用医薬組成物 |
US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
AU2013255885C1 (en) | 2012-05-03 | 2018-04-26 | Janssen Sciences Ireland Uc | Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections |
KR20160072140A (ko) | 2013-11-06 | 2016-06-22 | 얀센 사이언시즈 아일랜드 유씨 | 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형 |
-
2013
- 2013-05-02 AU AU2013255885A patent/AU2013255885C1/en active Active
- 2013-05-02 WO PCT/EP2013/059079 patent/WO2013164380A1/en active Application Filing
- 2013-05-02 CA CA2866230A patent/CA2866230C/en active Active
- 2013-05-02 JP JP2015509432A patent/JP6349304B2/ja active Active
- 2013-05-02 KR KR1020147028656A patent/KR102240042B1/ko active IP Right Grant
- 2013-05-02 CN CN201380023084.4A patent/CN104394846B/zh active Active
- 2013-05-02 BR BR112014026957A patent/BR112014026957A8/pt not_active Application Discontinuation
- 2013-05-02 NZ NZ630040A patent/NZ630040A/en unknown
- 2013-05-02 SG SG10201607288VA patent/SG10201607288VA/en unknown
- 2013-05-02 RU RU2014148544A patent/RU2650636C2/ru active
- 2013-05-02 US US14/398,573 patent/US9682096B2/en active Active
- 2013-05-02 EP EP13722334.3A patent/EP2846767B1/en active Active
- 2013-05-02 MX MX2014013256A patent/MX2014013256A/es unknown
- 2013-05-02 IN IN2359MUN2014 patent/IN2014MN02359A/en unknown
- 2013-05-02 ES ES13722334T patent/ES2911116T3/es active Active
- 2013-05-02 SG SG11201406208QA patent/SG11201406208QA/en unknown
-
2014
- 2014-10-15 CO CO14228077A patent/CO7101247A2/es unknown
- 2014-10-29 CL CL2014002929A patent/CL2014002929A1/es unknown
-
2015
- 2015-04-27 HK HK15104025.4A patent/HK1203390A1/xx unknown
-
2016
- 2016-06-13 US US15/180,603 patent/US9987300B2/en active Active
-
2018
- 2018-05-07 US US15/972,840 patent/US10485816B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10485816B2 (en) | 2019-11-26 |
SG11201406208QA (en) | 2014-11-27 |
CN104394846B (zh) | 2018-10-19 |
CO7101247A2 (es) | 2014-10-31 |
US20150140042A1 (en) | 2015-05-21 |
KR20150008855A (ko) | 2015-01-23 |
BR112014026957A8 (pt) | 2018-01-16 |
EP2846767B1 (en) | 2022-01-26 |
US20180325939A1 (en) | 2018-11-15 |
SG10201607288VA (en) | 2016-10-28 |
KR102240042B1 (ko) | 2021-04-14 |
BR112014026957A2 (pt) | 2017-06-27 |
EP2846767A1 (en) | 2015-03-18 |
HK1203390A1 (en) | 2015-10-30 |
NZ630040A (en) | 2016-10-28 |
MX2014013256A (es) | 2015-01-16 |
JP6349304B2 (ja) | 2018-06-27 |
CN104394846A (zh) | 2015-03-04 |
US20160296551A1 (en) | 2016-10-13 |
AU2013255885B2 (en) | 2017-10-05 |
JP2015515968A (ja) | 2015-06-04 |
AU2013255885A1 (en) | 2014-09-25 |
RU2650636C2 (ru) | 2018-04-16 |
IN2014MN02359A (es) | 2015-08-14 |
RU2014148544A (ru) | 2016-06-27 |
US9682096B2 (en) | 2017-06-20 |
WO2013164380A1 (en) | 2013-11-07 |
CA2866230A1 (en) | 2013-11-07 |
US9987300B2 (en) | 2018-06-05 |
ES2911116T3 (es) | 2022-05-17 |
CA2866230C (en) | 2020-08-18 |
AU2013255885C1 (en) | 2018-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014002929A1 (es) | Composicion que comprende ácido poliinosínico - policitidílico (poli (i:c) ) y un polimero portador; y sus usos para el tratamiento de infecciones de las vías respiratorias altas. | |
CL2021000008A1 (es) | Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) | |
SMT201700034B (it) | Composti di urea biciclica, tiourea, guanidina e cianoguanidina utili per il trattamento del dolore | |
CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
BR112014020345A2 (pt) | Medicamentos antivirais para o tratamento da infecção por arenavírus | |
DK3206715T3 (da) | Anvendelse af cannabidiol i behandling af tuberøs sklerosekompleks | |
CL2014003643A1 (es) | Compuesto derivado de éster del ácido 2-aminonicotínico y bactericida que contiene el mismo como ingrediente activo. | |
UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
DK2935303T3 (da) | 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV | |
ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
ES2769863T8 (es) | 7-hidroxi-cannabidivarín (7-OH-CBDV) para usar en el tratamiento de la epilepsia | |
CL2013003019A1 (es) | Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih. | |
CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
UY34201A (es) | Compuestos de azaindol y métodos para el tratamiento de vih. | |
BR112014028602A2 (pt) | formulação líquida. | |
CL2015001724A1 (es) | Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros. | |
CL2014003429A1 (es) | Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia. | |
UY34725A (es) | Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos. | |
DK2773648T3 (da) | Farmaceutiske forbindelser til anvendelse i behandlingen af clostridium difficile-infektion | |
DK3040336T3 (da) | Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande | |
CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
CL2013003563A1 (es) | Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma. | |
DK2522342T3 (da) | Topisk formulering til behandling af hyperkeratonisk hud | |
CR20140263A (es) | Composicion herbicida que contiene acido de 4-amino-3-cloro-6-(-4-cloro-2-fluor-3-metoxifenil) piridina-2-carboxilico, o los derivados del mismo y fluroxipir, o los derivados del mismo | |
CL2014002522A1 (es) | Agente inmunomodulador y usos para el mismo |